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Abstract
Background: The variable penetrance of ovarian cancer in BRCA1 mutation carriers suggests that
other genetic or environmental factors modify disease risk. The C to T transition in the 3'
untranslated region of the prohibitin (PHB) gene alters mRNA function and has recently been
shown to be associated with hereditary breast cancer risk in Polish women harbouring BRCA1
mutations.
Methods: To investigate whether the PHB 3'UTR polymorphism also modifies hereditary ovarian
cancer risk, we performed a case-control study among Polish women carrying one of the three
common founder mutations (5382insC, 300 T > G, 4154delA) including 127 ovarian cases and 127
unaffected controls who had both breasts and ovaries intact. Controls were matched to cases by
year of birth and BRCA1 mutation. Genotyping analysis was performed using PCR-based restriction
fragment length polymorphism analysis. Odds ratios (OR) were calculated using conditional and
penalized univariable and multivariable logistic regression.
Results: A comparison of the genotype frequencies between cases and controls revealed no
association of the PHB 3'UTR _CT+TT genotypes with ovarian cancer risk (ORadj 1.34; 95% CI,
0.59–3.11).
Conclusion: Our data suggest that the PHB 3'UTR polymorphism does not modify ovarian cancer
risk in women carrying one of the three Polish BRCA1 founder mutations.
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Background
Women harboring BRCA1  germ line mutations have a
high life time risk of developing ovarian cancer, ranging
from 16% in specific ethnic groups [1] to 63% in highly
selected families with multiple affected individuals [2].
These differences suggest that the penetrance of BRCA1
mutations is modified by other genetic and/or environ-
mental factors. A candidate modifier of hereditary ovarian
cancer risk is the prohibitin gene (PHB, OMIM 176705).
The encoded gene product binds to the retinoblastoma
protein, resulting in the suppression of E2F-mediated
transcription, and the p53 tumor suppressor, which even-
tuates in increased p53-mediated transcriptional activity
[3-5]. The 3'untranslated region (3'UTR) of the PHB gene
encodes a tumor suppressive trans-acting regulatory RNA
molecule [6] and acts as a cell cycle inhibitor between G1
and S phase when microinjected into normal mammary
epithelial cells and other cancer cell lines [7,8]. A func-
tional single nucleotide polymorphism (SNP) in the PHB
gene changing a cytosine to a thymine at position 1630 in
the 3'UTR (rs6917) has been identified that lacks the anti-
proliferative activity [7] and significantly reduces cell
motility [9].
The T allele of the PHB 3'UTR polymorphism has recently
been shown to be associated with an increased risk of
breast cancer (ORadj, 2.12; 95% CI, 1.23–3.70) [10] in
Polish women carrying one of the three common BRCA1
founder mutations that account for approximately 90% of
all detected BRCA1  mutations detected in this country
[11,12]. In a North-American study, the T allele was also
associated with an increased risk of breast cancer, particu-
larly in women with a breast cancer diagnosis before the
age of 50 years who had at least one first-degree relative
with the disease [13]. However, these findings were not
reproduced in two other case-control studies conducted in
Australia and Great Britain [14,15].
Since nothing is known about the influence of the PHB
3'UTR polymorphism on hereditary ovarian cancer risk,
we performed a case-control study among Polish women
carrying one of the three common BRCA1 founder muta-
tions, comprising 127 ovarian cases and 127 matched
controls.
Methods
Study participants
The Hereditary Cancer Registry at the Pomeranian Medi-
cal University in Szczecin, Poland contains clinical and
epidemiological data collected from 1997 and 2002 from
1,940 individuals carrying one of the three common
Polish BRCA1 founder mutations: 5382insC, 300 T > G
and 4154delA.
From the 1,940 registered BRCA1 mutation carriers, 254
female Polish carriers constituting 127 case-control pairs
for whom DNA samples were available were selected for
this study. Controls were matched to cases by year of birth
(within 2 years), and BRCA1 mutation (5382insC, 300 T
> G, 4154delA). They were included as controls if they
were unaffected by any type of cancer and had not under-
gone prophylactic mastectomy, adnexectomy or tubal
ligation prior to the age at which ovarian cancer was diag-
nosed in the corresponding case. They were considered as
cases if they were diagnosed with invasive primary ovarian
cancer (excluding borderline ovarian carcinoma) and had
not undergone prophylactic mastectomy, adnexectomy or
tubal ligation prior to the age of ovarian cancer diagnosis.
The research was approved by the Ethics Committee of
Pomeranian Medical University in Szczecin, Poland and
all participants gave informed consent prior to enrolling
in the study. All women received genetic counseling prior
to and at the provision of their test results.
Genotyping analysis
Genotyping of the 1630_C > T polymorphism (rs6917) in
the 3'UTR of the PHB gene (Genbank accession number
NT_010783.13) in 254 BRCA1 mutation carriers was per-
formed by PCR-based restriction fragment length poly-
morphism analysis as previously described [10].
Genotyping was carried out by two independent person-
nel who were blinded to the disease status of the samples.
Several samples were sequenced on an ABI prism 377
DNA Sequencer (Perkin-Elmer, Foster City, USA) to con-
firm the genotypes. The reproducibility of the genotyping
data was assessed by repeated analysis of 40/254 (16%)
randomly selected DNA samples. Concordance for these
quality control samples was 100%. Genotypes were
obtained for all 254 BRCA1 mutation carriers constituting
PCR concordance rate of 100%.
Statistical analysis
Statistical modelling of the study on 127 ovarian cancer
case-control pairs revealed a 55.3% power to detect an OR
of 2.00 and an 81.5% power to detect an OR of 2.50. This
is based on the assumption that the probability of observ-
ing CT+TT genotypes among control patients is 0.2. For
the correlation, phi, between matched case and control
patients to observe these genotypes we assumed a value of
phi = 0.2 according the recommendation of Dupont [16].
This power calculation further assumes the use of a Chi-
Square test with a 0.05 significance level.
Risk estimates for the development of ovarian cancer were
calculated as odds ratios (ORcrude) with 95% confidence
interval (CI) using a conditional logistic regression model
by maximising the conditional likelihood for all 127 case-BMC Cancer 2008, 8:90 http://www.biomedcentral.com/1471-2407/8/90
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control pairs. For 83 pairs, we adjusted the risks for poten-
tial ovarian cancer risk factors, referred to as adjusted odds
ratios (ORadj), by including age at menarche, age at first
live birth, parity (0, 1, 2, 3, 4, 4+ children), lifetime cumu-
lative months of breastfeeding (≤12 and >12 months),
oral contraceptive (OC) use (<5 and ≥5 years), hormone
replacement therapy (HRT) use (never, ever), smoking
(<4 and ≥4 pack-years) and body mass index (BMI) (at age
of breast cancer diagnosis for cases and at corresponding
age for controls) in the penalized-likelihood logistic
regression model [17].
Age comparisons among carriers of different genotypes
were performed using the Mann-Whitney U-test. Exact
95% confidence intervals were calculated for binomial
probabilities. The statistical analyses were done using the
software package R, version 2.3.1 [18] with packages "sur-
vival", version 2.26, and "logistf", version 1.06. In order to
account for a potential bias due to the presence of rela-
tives, we performed a second analysis using only unre-
lated study subjects. After exclusion of the pairs with
relatives, ORcrude were calculated for 104 pairs and ORadj
for 69 pairs. Two-sided p values of 0.05 or less were con-
sidered as statistically significant.
Results
Description of the study participants
A total of 254 BRCA1  mutation carriers including 127
ovarian cancer cases and 127 unaffected controls were
included in this study. All mutation carriers were selected
from families with at least one ovarian cancer diagnosed
at any age or with multiple cases of breast and ovarian
cancer. Controls were matched to cases by year of birth
and  BRCA1  mutation and were similar to cases with
respect to potential ovarian cancer risk factors including
year of birth, age at first live birth, age at menarche, BMI,
parity, breastfeeding, and smoking. In contrast, OC use of
5 years and more and HRT use were less frequently
reported by ovarian cancer cases than by controls (0 cases,
8 controls; 2 cases and 11 controls, respectively; Table 1).
These differences were not considered relevant because of
the small number of individuals.
Table 1: Comparison of ovarian cancer cases and matched controls
Characteristic Cases (n = 83) n (%) Controls (n = 83) n (%)
Year of birth (median) 1953 (range 1928–1971) 1953 (range 1929–1971)
Age of 1st live birth (median) 22 (range 16–38) 23 (range 17–35)
Age at menarche (median) 14 (range 10–17) 14 (range 9–18)
BMI (median) 25 (range 19–38) 25 (range 17–44)
Age (median) 45a (range 25–71) 49b (range 31–73)
Parity
07  ( 8 ) 7  ( 8 )
11 1  ( 1 3 ) 1 2  ( 1 4 )
24 3  ( 5 2 ) 4 1  ( 5 0 )
31 3  ( 1 6 ) 1 7  ( 2 0 )
47  ( 8 ) 4  ( 5 )
>4 2 (3) 2 (3)
Breastfeedingc
≤ 12 months 20 (26) 23 (30)
>12 months 56 (74) 53 (70)
OC use
<5 years 83 (100) 75 (90)
≥ 5 years 0 (0) 8 (10)
HRT
Never 81 (97) 72 (87)
Ever 2 (3) 11 (13)
Smokingd
<4 pack-years 56 (67) 52 (63)
≥ 4 pack-years 24 (29) 31 (37)
BRCA1 mutation
5382insC 61 (74) 61 (74)
300T>G 16 (19) 16 (19)
4154delA 6 (7) 6 (7)
BMI: body mass index; OC: oral contraceptive; HRT: hormone replacement therapy.
a Age at diagnosis of ovarian cancer.
b Age at the time of matching.
c Nulliparous women were excluded.
d Missing information on smoking status from three cases.BMC Cancer 2008, 8:90 http://www.biomedcentral.com/1471-2407/8/90
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Comparison of PHB 3'UTR T allele and genotype 
frequencies among ovarian cancer cases and controls
Among BRCA1 carriers, no difference in the T allele fre-
quency between ovarian cancer cases and controls was
observed (27/254, 11%; 95% CI 7.12–15.10 vs. 25/254,
10%, 95% CI 6.50–14.20) (Fisher's exact test, p = 0.88).
The genotype distribution among all case-control pairs (n
= 127) and among those with risk factor information (n =
83) are shown in Table 2. There was no difference in
CT+TT genotype frequencies among cases and controls
(ORcrude, 1.05; 95% CI, 0.54–2.04; ORadj, 1.34; 95% CI
0.59–3.11). After exclusion of related study subjects, sim-
ilar results were obtained (ORcrude, 1.06; 95% CI 0.55–
2.01; ORadj, 1.38; 95% CI 0.57–3.41).
Among all cases, women with the CT+TT genotypes were
diagnosed at a median age one year younger than women
with the CC genotype [45 years (range 35–71 years) vs. 46
years (range 25–71 years)], but this age difference was not
statistically significant (Mann-Whitney test, p = 0.77).
Discussion
In the present study we investigated the effect of PHB
3'UTR polymorphism on the risk of ovarian cancer in
BRCA1 mutation carriers. While one investigation of the
PHB polymorphism in an ovarian cancer population has
been previously reported [19], nothing is known about
its' influence in women with predisposing mutations in
the BRCA1 gene.
In this matched case-control study we did not find an
association of the PHB  CT+TT genotypes with ovarian
cancer risk in selected women harbouring one of the path-
ogenic BRCA1 founder mutations. This result remained
after adjusting for known and putative ovarian cancer risk
factors including age at menarche, age of first live birth,
parity, breastfeeding, OC use, HRT, smoking status and
BMI [20,21] as well as after exclusion of those study par-
ticipants who were related to one another suggesting that
confounding due to these variables was unlikely.
Outside the context of hereditary ovarian cancer there is
only one Australian study that has investigated the contri-
bution of the PHB 3'UTR polymorphism to ovarian cancer
risk. In this case-control study on 553 ovarian cancer cases
and 300 unaffected controls also no association of the
CT+TT genotypes with ovarian cancer risk has been found
[19]. When taken together, it appears that our results and
those reported by Spurdle et al. [19] do not support a role
for PHB polymorphism in sporadic and hereditary ovar-
ian cancer risk.
This finding is in contrast to our observation that the PHB
polymorphism acts as a modifier of BRCA1-associated
breast cancer risk in a similar collective of 258 breast can-
cer patients and 258 matched controls [10]. The most
likely explanation for the difference of effect between
breast cancer and ovarian cancer patients within our study
set is in the underlying disease mechanisms involved in
breast cancer compared to ovarian cancer. At this stage
what these differences are remains to be resolved. How-
ever, it also cannot be ruled out that due to the smaller
size of the ovarian cancer study no association was
detected. Thus, larger studies are warranted to confirm
these preliminary results.
Conclusion
In summary, the 3'UTR polymorphism in PHB appears
not to be associated with ovarian cancer risk in women
carrying of one of the three Polish BRCA1 founder muta-
Table 2: Association of the PHB_1630_C > T polymorphism with ovarian cancer risk in BRCA1 carriers
All cases and controls
Genotype Cases (n = 127) n (%) Controls (n = 127) n (%) ORcrude
b (95% CI) p
PHB_1630_C > T
CC 101 (80) 102 (80) 1.00 (reference)
CT+TTa 26 (20) 25 (20) 1.05 (0.54–2.04) 1.00
Cases and controls with risk factor information
Genotype Cases (n = 83) n (%) Controls (n = 83) n (%) ORadj
c (95% CI) p
PHB_1630_C > T
CC 64 (77) 65 (78) 1.00(reference)
CT+TTa 19 (23) 18 (18) 1.34 (0.59–3.11) 0.49
a Due to the low proportion of <3% in patients and controls, CT and TT genotypes were combined.
b ORcrude: crude odds ratio.
c ORadj: odds ratio adjusted for age at menarche, age of first live birth, parity, breastfeeding, OC use, HRT, smoking and BMI.BMC Cancer 2008, 8:90 http://www.biomedcentral.com/1471-2407/8/90
Page 5 of 5
(page number not for citation purposes)
tions even when accounting for environmental influences
that are considered important in disease risk determina-
tion. The identification of genetic ovarian cancer risk
modifiers remains to be accomplished.
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